Literature DB >> 18928665

Uterine papillary serous carcinoma: state of the state.

R Wendel Naumann1.   

Abstract

Uterine papillary serous carcinoma (UPSC) is an aggressive form of endometrial cancer that is likely to present with deep myometrial invasion and lymph vascular involvement. By the time most affected women are diagnosed, the UPSC has spread outside the uterus. Because many reports include patients who are not completely staged, the risk of recurrence in stage I patients has likely been overestimated. Recently, several large series of well-staged patients have demonstrated that survival in stage I patients is similar to that of poorly differentiated endometrioid tumors. Because of the high risk of extrauterine spread, all patients with UPSC should have an extended surgical staging procedure, including lymphadenectomy and omentectomy. Chemotherapy with or without local or regional radiation is probably the most effective adjuvant therapy in both early and advanced disease. Because patients with stage I UPSC are still at significant risk of recurrence, adjuvant therapy is often recommended for all patients. It has been difficult to conduct prospective randomized trials for patients with UPSC because of the rare nature of these cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18928665     DOI: 10.1007/s11912-008-0076-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  40 in total

Review 1.  Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.

Authors:  R S Smith; D S Kapp; Q Chen; N N Teng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.

Authors:  R E Bristow; L R Duska; F J Montz
Journal:  Gynecol Oncol       Date:  2001-04       Impact factor: 5.482

3.  Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).

Authors:  F V Price; S K Chambers; M L Carcangiu; E I Kohorn; P E Schwartz; J T Chambers
Journal:  Gynecol Oncol       Date:  1993-12       Impact factor: 5.482

4.  Treatment of uterine papillary serous carcinoma with paclitaxel.

Authors:  L Ramondetta; T W Burke; C Levenback; M Bevers; D Bodurka-Bevers; D M Gershenson
Journal:  Gynecol Oncol       Date:  2001-07       Impact factor: 5.482

5.  What staging surgery should be performed on patients with uterine papillary serous carcinoma?

Authors:  J P Geisler; H E Geisler; M E Melton; M C Wiemann
Journal:  Gynecol Oncol       Date:  1999-09       Impact factor: 5.482

6.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Authors:  P J Hoskins; K D Swenerton; J A Pike; F Wong; P Lim; C Acquino-Parsons; N Lee
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

7.  Uterine papillary serous carcinoma: patterns of metastatic spread.

Authors:  B A Goff; D Kato; R A Schmidt; M Ek; J A Ferry; H G Muntz; J M Cain; H K Tamimi; D C Figge; B E Greer
Journal:  Gynecol Oncol       Date:  1994-09       Impact factor: 5.482

8.  Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.

Authors:  A P Vaidya; R Littell; C Krasner; L R Duska
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

9.  Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.

Authors:  Wenxin Zheng; Sharon X Liang; Herbert Yu; Thomas Rutherford; Setsuko K Chambers; Peter E Schwartz
Journal:  Int J Surg Pathol       Date:  2004-07       Impact factor: 1.271

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  9 in total

1.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

2.  Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Susanna Syriac; Heidi Godoy; Nefertiti Dupont; Song Liu; Kunle Odunsi
Journal:  Gynecol Oncol       Date:  2011-10-19       Impact factor: 5.482

3.  Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Joshua Kesterson; Kimberly Clark; Laketa Monhollen; Kunle Odunsi; Shashikant Lele; Song Liu
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

4.  Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Joshua Kesterson; Susanna Syriac; Kimberly Clark; Peter J Frederick; Shashikant Lele; Song Liu
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

5.  Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Shashikant Lele; Peter J Frederick; Tanja Pejovic; Song Liu
Journal:  BMC Res Notes       Date:  2012-01-24

6.  Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel.

Authors:  Manabu Seino; Tsuyoshi Ohta; Akiko Sugiyama; Hirotsugu Sakaki; Takeshi Sudo; Seiji Tsutsumi; Shogo Shigeta; Hideki Tokunaga; Masafumi Toyoshima; Nobuo Yaegashi; Satoru Nagase
Journal:  Oncotarget       Date:  2018-08-10

Review 7.  The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review.

Authors:  Valentina Lancellotta; Francesca De Felice; Lisa Vicenzi; Alfredo Antonacci; Valentina Cerboneschi; Sara Costantini; Daniela di Cristino; Luca Tagliaferri; Annamaria Cerrotta; Andrea Vavassori; Sergio Gribaudo; Alessandro Colombo; Francesco Lucà; Raffaele Barbara; Monica Mangoni; Francesco Marampon; Daniela Musio; Filippo Bellati; Francesco Torcia; Vincenzo Tombolini; Mattia Falchetto Osti; Vitaliana De Sanctis
Journal:  J Contemp Brachytherapy       Date:  2020-02-28

8.  The role of hypoxic-inducible factor (HIF1α) and aldolaseC protein in endometrial carcinogenesis: a retrospective study of 279 patients.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Damanzoopinder Samrao; Teodulo Menesses; Heidi Godoy; Faith Ough; Shashikant Lele; Song Liu; Tanja Pejovic
Journal:  BMJ Open       Date:  2012-08-24       Impact factor: 2.692

9.  Adrenal Metastasis from Uterine Papillary Serous Carcinoma.

Authors:  Sandeep Singh Lubana; Navdeep Singh; Sandeep S Tuli; Barbara Seligman
Journal:  Am J Case Rep       Date:  2016-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.